4.0 Article

Mortality and cause of death in Japanese patients with rheumatoid arthritis based on a large observational cohort, IORRA

期刊

SCANDINAVIAN JOURNAL OF RHEUMATOLOGY
卷 39, 期 5, 页码 360-367

出版社

TAYLOR & FRANCIS LTD
DOI: 10.3109/03009741003604542

关键词

-

资金

  1. Abbott Japan Co., Ltd.
  2. Asahikasei Kuraray Medical Co., Ltd.
  3. Asahikasei Pharma Corporation
  4. Astellas Pharma Inc.
  5. AstraZeneca
  6. Banyu Pharmaceutical Co., Ltd.
  7. Chugai Pharmaceutical Co., Ltd.
  8. Daiichi Fine Chemical Co., Ltd.
  9. Daiichi Sankyo Co., Ltd.
  10. Dainippon Sumitomo Pharma Co., Ltd.
  11. Eisai Co., Ltd.
  12. GlaxoSmithKline
  13. Janssen Pharmaceutical
  14. Japan Tobacco Inc.
  15. Kaken Pharmaceutical Co., Ltd.
  16. Kissei Pharmaceutical Co., Ltd.
  17. Kowa Pharmaceutical Co., Ltd.
  18. Mitsubishi Chemical Medience Corporation
  19. Mitsubishi Tanabe Pharma Corporation
  20. Nippon Chemiphar Co., Ltd.
  21. Nippon Shinyaku Co., Ltd.
  22. Novartis Pharma
  23. Otsuka Pharmaceutical Co., Ltd.
  24. Pfizer Japan Inc.
  25. Sanofi-aventis
  26. Santen Pharmaceutical Co., Ltd.
  27. Sanwa Kagaku Kenkyusho Co., Ltd.
  28. Sekisui Medical Co., Ltd.
  29. Taisho Toyama Pharmaceutical Co., Ltd.
  30. Takeda Pharmaceutical Company Limited
  31. Teijin Pharma Limited
  32. Torii Pharmaceutical Co., Ltd.
  33. Toyama Chemical Co., Ltd.
  34. UCB Japan Co., Ltd.
  35. Wyeth
  36. Zeria Pharmaceutical Co., Ltd.

向作者/读者索取更多资源

Methods: The IORRA cohort is a large observational cohort established in 2000 at the Institute of Rheumatology, Tokyo Women's Medical University. Essentially, all RA patients were registered and clinical parameters were assessed biannually. For patients who failed to participate in subsequent surveys, simple queries were mailed to confirm survival. Standardized mortality ratios (SMRs) were calculated and mortality risk factors were analysed using a Cox proportional hazard model. Results: We analysed 7926 patients (81.9% females; mean age 56.3 +/- 13.1 years; mean disease duration 8.5 +/- 8.3 years) with RA who enrolled in IORRA from October 2000 to April 2007. During the observational period (35 443.0 person-years), 289 deaths were reported. Major causes of death included malignancies (24.2%), respiratory involvement (24.2%) including pneumonia (12.1%) and interstitial lung disease (ILD) (11.1%), cerebrovascular disease (8.0%), and myocardial infarction (7.6%). As death was not confirmed in all patients, the SMR was deduced to be between 1.46 [95% confidence interval (CI) 1.32-1.60] and 1.90 (95% CI 1.75-2.07) for all patients, between 1.45 (95% CI 1.22-1.70) and 1.70 (95% CI 1.45-1.97) for men, and between 1.46 (95% CI, 1.29-1.65) and 2.02 (95% CI 1.82-2.24) for women. Factors associated with increased mortality included male gender, older age, worse physical disability, positive rheumatoid factor (RF), corticosteroid use, and presence of ILD. Conclusion: The mortality of Japanese RA patients is comparable to that in previous reports from western countries, even though the causes of death were significantly different.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.0
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据